2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
暂无分享,去创建一个
S. H. van der Burg | D. Filippov | Gerbrand J. van der Heden van Noort | H. Overkleeft | G. A. van der Marel | C. Melief | Selina Khan | F. Ossendorp | Jimmy J. Weterings
[1] R. Coffman,et al. Development of TLR inhibitors for the treatment of autoimmune diseases , 2008, Immunological reviews.
[2] Jian Huang,et al. Toll-like receptors in inflammation, infection and cancer. , 2007, International immunopharmacology.
[3] L. Joosten,et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. , 2007, Arthritis and rheumatism.
[4] N. Gay,et al. Structure and function of Toll receptors and their ligands. , 2007, Annual review of biochemistry.
[5] B. Beutler,et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.
[6] S. Akira,et al. Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.
[7] H. Cottam,et al. Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists. , 2006, Bioorganic & medicinal chemistry letters.
[8] W. Sterry,et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases , 2006, The British journal of dermatology.
[9] S. H. van der Burg,et al. Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. , 2006, Bioorganic & medicinal chemistry letters.
[10] Tomoaki Nakamura,et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. , 2006, Journal of medicinal chemistry.
[11] Yu-Tseung Liu,et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Tomai,et al. Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.
[13] A. Kurimoto,et al. Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: potent interferon inducing agents in monkeys. , 2004, Chemical & pharmaceutical bulletin.
[14] A. Kurimoto,et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. , 2004, Bioorganic & medicinal chemistry.
[15] A. Kurimoto,et al. Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents. , 2003, Bioorganic & medicinal chemistry.
[16] A. Kurimoto,et al. Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. , 2003, Bioorganic & medicinal chemistry.
[17] H. Sajiki,et al. Synthesis and biological evaluation of 2,8-disubstituted 9-benzyladenines: discovery of 8-mercaptoadenines as potent interferon-inducers. , 2003, Bioorganic & medicinal chemistry.
[18] H. Sajiki,et al. Efficient synthesis of 2,9-disubstituted 8-hydroxyadenine derivatives. , 2003, Organic & biomolecular chemistry.
[19] A. Kurimoto,et al. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. , 2002, Journal of medicinal chemistry.
[20] S. Akira,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.
[21] N. Strominger,et al. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation , 2001, Brain Research Bulletin.
[22] K. Beutner,et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.
[23] D. Reding,et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. , 1993, Cancer research.
[24] D. Bernstein,et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.
[25] Sun Hee Jin,et al. Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. , 2009, The Journal of investigative dermatology.
[26] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.